Bioanalytical liquid chromatographic method validation. A review of current practices and procedures

被引:149
作者
Rosing, H [1 ]
Man, WY [1 ]
Doyle, E [1 ]
Bult, A [1 ]
Beijnen, JH [1 ]
机构
[1] Netherlands Canc Inst, Slotervaart Hosp, Dept Pharm & Pharmcol, NL-1066 EC Amsterdam, Netherlands
关键词
D O I
10.1081/JLC-100101455
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Validation of analytical methodologies is widely accepted as pivotal before they are put into routine use. Within the guidelines issued by Regulatory Authorities, there still exists scope for individual interpretation with respect to their conduct and acceptance criteria. The intention of this paper is to review the performances used and to provide practical approaches for determining selectivity, specificity, limit of detection, lower limit of quantitation, linearity, range, accuracy, precision, recovery, stability, ruggedness, and robustness of liquid chromatographic methods to support pharmacokinetic studies. A survey of recent literature on liquid chromatographic procedures used in the bioanalysis of anticancer drugs revealed that very variable standards were employed for validation.
引用
收藏
页码:329 / 354
页数:26
相关论文
共 70 条
[51]   Bio-analysis of docetaxel and hydroxylated metabolites in human plasma by high-performance liquid chromatography and automated solid-phase extraction [J].
Rosing, H ;
Lustig, V ;
Koopman, FP ;
Huinink, WWT ;
Beijnen, JH .
JOURNAL OF CHROMATOGRAPHY B, 1997, 696 (01) :89-98
[52]   Determination of GI147211 in human blood by HPLC with fluorescence detection [J].
Selinger, K ;
Smith, G ;
Depee, S ;
Aureche, C .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1995, 13 (12) :1521-1530
[53]   ANALYTICAL METHODS VALIDATION - BIOAVAILABILITY, BIOEQUIVALENCE, AND PHARMACOKINETIC STUDIES [J].
SHAH, VP ;
MIDHA, KK ;
DIGHE, S ;
MCGILVERAY, IJ ;
SKELLY, JP ;
YACOBI, A ;
LAYLOFF, T ;
VISWANATHAN, CT ;
COOK, CE ;
MCDOWALL, RD ;
PITTMAN, KA ;
SPECTOR, S .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1992, 81 (03) :309-312
[54]   SIMULTANEOUS DETERMINATION OF A NEW ANTICANCER AGENT (NB-506) AND ITS ACTIVE METABOLITE IN HUMAN PLASMA AND URINE BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH ULTRAVIOLET DETECTION [J].
TAKENAGA, N ;
ISHII, Y ;
MONDEN, S ;
SASAKI, Y ;
HATA, S .
JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS, 1995, 674 (01) :111-117
[55]  
Thompson M., 1990, ANAL P, V27, P142
[56]  
THORBECK LD, 1996, PHARM TECHNOL, V3, P168
[57]   A NEW APPROACH FOR DEALING WITH THE STABILITY OF DRUGS IN BIOLOGICAL-FLUIDS [J].
TIMM, U ;
WALL, M ;
DELL, D .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1985, 74 (09) :972-977
[58]  
US FDA, 1994, REV GUID VAL CHROM M
[59]  
*US PHARM CONV INC, 1995, VAL COMP METH, P1982
[60]   DETERMINATION OF INTOPLICINE, A NEW ANTITUMOR DRUG, IN HUMAN FECES BY NORMAL-PHASE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH FLUORESCENCE DETECTION [J].
VANGIJN, R ;
KUIJS, S ;
ROSING, H ;
DUBBELMAN, AC ;
VANTELLINGEN, O ;
HUININK, WWT ;
PINEDO, HM ;
BEIJNEN, JH .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1993, 11 (11-12) :1345-1348